Highest-materiality recent filing
Teladoc Health Q1 2026 Revenue Falls 2% to $613.8M, Net Loss Narrows to $63.8M
First Quarter 2026 revenue of $613.8 million, down 2% year-over-year
Teladoc Q4 revenue flat at $642M, net loss narrows; FY2026 revenue guidance $2.47-2.587B
Q4 2025 revenue $642.3M (flat YoY); net loss $25.1M vs $48.4M loss; adjusted EBITDA $83.8M (+12% YoY).
Teladoc Q3 revenue down 2% to $626.4M; net loss widens to $49.5M; adj. EBITDA falls 16%
Revenue $626.4M (-2% YoY); net loss $49.5M ($0.28 per share) vs. $33.3M loss a year ago.
Teladoc Health CFO Mala Murthy resigns; preliminary Q3 revenue $626.4M, adj EBITDA $69.9M
CFO Mala Murthy to resign effective Nov 21, 2025; interim finance leaders reporting to CEO.
Net loss of $32.7M ($0.19 per share), improved from $837.7M loss in Q2 2024 which included $790M goodwill impairment.
Teladoc Q1 revenue down 3% to $629M; net loss widens on $59M goodwill impairment; acquires UpLift
Revenue $629.4M (-3% YoY); net loss $93M ($0.53/sh) includes $59.1M goodwill impairment.
Teladoc Health Q4 revenue $640.5M (-3% YoY); full-year net loss $1.0B on $790M goodwill impairment
Q4 revenue $640.5M (-3% YoY); full-year revenue $2,569.6M (-1% YoY).
Teladoc Q3 revenue $640.5M (-3% YoY), net loss narrows to $0.19 EPS; BetterHelp revenue down 10%
Revenue $640.5M (-3% YoY); net loss $33.3M ($0.19 per share) vs $57.1M loss last year.
Q2 revenue $642.4M (-2% YoY); net loss $837.7M ($4.92/sh) includes $790M goodwill impairment for BetterHelp.
Teladoc Health names Chuck Divita as CEO effective June 10, 2024
Charles Divita appointed CEO and board member; Mala Murthy returns to CFO role.
Teladoc Health Q1 revenue +3% to $646.1M; adjusted EBITDA +20% to $63.1M
Revenue $646.1M (+3% YoY); net loss $81.9M ($0.49 EPS) vs $69.2M loss in Q1 2023.
On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure.
Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer.
On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024.
appointed Mr. Divita as a director of the Company.
Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer.
Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer.
Max materiality 0.85 · Median 0.55 · Most common event earnings